Business
Tata Sierra 2025: Check Expected Price, Key Features And Stylish Design
Tata Sierra 2025: Tata Motors is all set to reintroduce its iconic SUV, the Tata Sierra, in 2025. The upcoming model brings back the beloved design of the original Sierra while adding a host of modern features, advanced technology, and multiple powertrain options, including electric. According to rumours, the SUV is expected to be priced between Rs 12 lakh to 25 lakh (ex-showroom).
Classic Design With a Modern Touch
The Tata Sierra 2025 comes with the classic boxy silhouette that made the original model a fan favourite. One of its most distinctive features, the “infinite window” design, also makes a comeback, preserving the SUV’s signature look. Tata has enhanced this retro design with modern styling elements such as LED light bars, flush door handles, and blackened C and D pillars, which give the Sierra a sleek appearance.
The blend of old-school charm and new-age detailing has generated strong excitement among SUV enthusiasts. With this launch, Tata aims to recreate the original Sierra while appealing to modern buyers seeking style and innovation.
Advanced and Tech-Focused Interior
The Tata Sierra 2025 features a high-tech triple-screen dashboard setup, consisting of a digital driver display, a central infotainment screen, and an additional screen for the co-driver. This setup offers easy access to key driving and entertainment functions.
The cabin will also feature Level 2 ADAS (Advanced Driver Assistance System), offering safety technologies such as a 360-degree camera, lane-keep assist, and dual-zone climate control. These features are designed to improve safety and convenience.
(Also Read: Oppo Reno 15 Series Set To Launch In China On Nov 17: Expected Models, Specs, Features)
Focus on Comfort and Luxury
Tata Motors is giving special attention to comfort in the Sierra 2025. The SUV will include features like a panoramic sunroof, ventilated seats, and connected car technology, enhancing both comfort and convenience. With these additions, the Sierra aims to deliver a premium driving experience comparable to higher-end SUVs in its segment.
The Sierra will also come equipped with seven airbags, a 360-degree camera, and additional driver-assistance features, ensuring maximum safety for passengers.
Multiple Engine Options
The upcoming Sierra will be available with petrol, diesel, and fully electric variants, offering buyers flexibility based on their preferences and driving needs.
Competition and Market Position
Once launched, the Tata Sierra 2025 will compete with SUVs such as the Hyundai Creta and Kia Seltos. While pricing is expected to be similar to these rivals, the Sierra’s latest design, advanced tech features, and the availability of an electric option are expected to set it apart in the crowded SUV market.
Instagram’s longtime lead Adam Mosseri arrived on Wednesday at a courtroom in Los Angeles.
Source link
Business
Novo Nordisk CEO sees 15 million-patient opportunity in Medicare coverage for obesity drugs
Novo Nordisk CEO Mike Doustdar on Wednesday said the company is aiming to capture around 15 million new patients, at least initially, when Medicare starts covering obesity treatments for the first time later this year.
Around 67 million Americans are covered by Medicare, but “when you take a look at specifically our products and the target group, I think around 15 million people would be a good number to target,” he told CNBC in an interview.
Medicare is slated to start covering obesity medicines for the first time later this year under the landmark “most favored nation” drug pricing deals that Novo and its chief rival Eli Lilly struck with President Donald Trump in November.
Health experts say the long-awaited coverage could broaden the market for the medicines and spur more private insurers to cover them. Some experts estimate that 20 million to 30 million Medicare patients are suffering from obesity and related conditions.
Doustdar said Medicare coverage, along with the launch of Novo’s new obesity pill and other factors, should help the company gradually boost prescription volumes and offset lower prices in the U.S. following that agreement with Trump.
But he said he doesn’t expect Medicare access to obesity treatments to open up overnight.
“Now, it would be great if we could find a way to get access very, very fast. But I think that would be a bit naive,” Doustdar said, pointing to the slow adoption seen among eligible patients with commercial insurance.
It’s a slightly more conservative tone on the initial impact of Medicare coverage compared to Lilly, which has cited that coverage as a key tailwind to its guidance this year. Last week, Lilly said it expects Medicare coverage to come online by July.
Meanwhile, Doustdar said Novo is in the midst of negotiations with the government on “exactly which month, which week that is going to be opening.”
Closing the market share gap
Novo is under pressure to claw back market share in the booming GLP-1 space from Lilly and cheaper, compounded copycats. Last week, Lilly said its share of the U.S. obesity and diabetes drug market increased to 60.5% in the fourth quarter, while Novo’s was 39.1%.
Novo has also highlighted a gap in the “preference share” for its weight loss treatment Wegovy versus Lilly’s rival injections. In the U.S., Novo estimates that between 7 and 8 patients out of 10 go to Lilly.
When asked how Novo plans to close that gap, Doustdar said one way to do so is “to do better on the pill.” The company’s Wegovy obesity pill has a head start compared to Lilly’s upcoming oral drug, orforglipron, which is expected to win approval from the Food and Drug Administration during the second quarter.
Mike Doustdar, left, CEO of Novo Nordisk, and David Ricks, CEO of Eli Lilly, listen as President Donald Trump speaks in the Oval Office during an event about weight-loss drugs on Nov. 6, 2025.
Andrew Caballero-Reynolds | Afp | Getty Images
Doustdar said Novo’s pill is slightly more effective than Lilly’s based on separate clinical trials, showing 16.6% weight loss compared to 12.4% with Lilly’s oral drug.
“If you use these two numbers, basically you have a 40% difference between the efficacy of these pills,” he said. “I think this is going to be a very main, main selling point of the pill.”
But Doustdar also pointed to the upcoming approval and launch of a higher dose – 7.2 milligram – of Wegovy that could help win market share from Lilly’s obesity treatment Zepbound.
That higher dose helps patients lose around 21% of their weight, which is “very much on par” with the highest dose of Zepbound, he said. Zepbound’s higher efficacy has been a key factor in driving more patients and prescribers away from choosing Wegovy, which has shown around 15% weight loss on average in clinical trials.
“When that comes to the market, my thought, my wish, my hope is that people will realize, OK, now we have two products with similar efficacy,” he said.
Charles Brohiri travelled without buying a ticket on 112 train journeys over a period of nearly two years.
Source link
I Loved My OpenClaw AI Agent—Until It Turned on Me
Ranking the top 12 men’s Coach of the Year contenders at midseason
Trump meets Netanyahu, with US-Iran nuclear diplomacy topping agenda
-
Entertainment5 days agoHow a factory error in China created a viral “crying horse” Lunar New Year trend
-
Business1 week agoNew York AG issues warning around prediction markets ahead of Super Bowl
-
Fashion1 week agoICE cotton slides as strong dollar, metal sell-off hit prices
-
Fashion1 week agoIntertextile Shanghai 2026 to debut pet boutique zone
-
Business5 days agoStock market today: Here are the top gainers and losers on NSE, BSE on February 6 – check list – The Times of India
-
Tech5 days agoNordProtect Makes ID Theft Protection a Little Easier—if You Trust That It Works
-
Tech5 days agoPrivate LTE/5G networks reached 6,500 deployments in 2025 | Computer Weekly
-
Business1 week agoWhy Are Gold Prices Swinging? Nirmala Sitharaman Breaks It Down